Informative noncompliance in endpoint trials - Test2 - elhamkhani - TriplyDB

Informative noncompliance in endpoint trials

Informative noncompliance in endpoint trials

http://www.wikidata.org/entity/Q24791524

about

Non-compliance with randomised allocation and missing outcome data in randomised controlled trials evaluating surgical interventions: a systematic review Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? A simulation study to evaluate the feasibility of the Cluster cmRCT design.Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes.Noncompliance in randomized controlled trials.Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results.

P2860

Q26786062-8D0ED17C-F949-4382-867E-C3C939E335E7 Q36114940-BB75461C-4503-469B-AD9C-67ACFEEF5C34 Q41103027-317FC59E-927A-43EA-AA2E-FC3A77FF3C2D Q42627798-1EE0C4E0-0F90-4EB4-B9F9-4FB72BE9A09E Q42773630-FAD75319-D75F-4972-8EA6-3AE53FA7B13F Q47316402-361C0F86-0D20-48A1-AB30-60BA1BA635F9 Q50246066-884D87C0-5D62-4552-8796-5C76974452E9

P2860

Informative noncompliance in endpoint trials

http://www.wikidata.org/entity/Q24791524

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Informative noncompliance in endpoint trials

@ast

Informative noncompliance in endpoint trials

@en

Informative noncompliance in endpoint trials

@nl

type

label

Informative noncompliance in endpoint trials

@ast

Informative noncompliance in endpoint trials

@en

Informative noncompliance in endpoint trials

@nl

prefLabel

Informative noncompliance in endpoint trials

@ast

Informative noncompliance in endpoint trials

@en

Informative noncompliance in endpoint trials

@nl

P1433

Q24791524-411EBD06-0A5E-4DAC-BC0E-57A41774B7F4

P1476

Q24791524-966A6204-7A3D-4E6B-80F6-E78194F30AEB

P2093

Q24791524-4B40E314-F7B4-436C-8A79-22FAB0BA357B

Q24791524-BD481DA6-4AD8-4356-A048-38723C584239

Q24791524-E8F091F4-EA14-4026-A2CA-60471EBE488F

P2860

Q24791524-09E53064-482D-4E7B-B812-B4F2C4BEC534

Q24791524-2A973EDC-49F9-4E4C-90D7-F50D5B3138C9

Q24791524-46B3F6D2-F7C7-4D83-B530-280A433C906C

Q24791524-641334FA-1FB4-42B4-914B-BFFD3DFC235F

Q24791524-904D18AB-7155-437D-953D-C39C08CCF07B

Q24791524-92BAFC35-0B4A-4307-B52B-CB844B5E4349

Q24791524-937FDB34-9FAF-4B0A-BFF0-03DD328CAE04

Q24791524-A4380D2F-B04C-44B5-95FD-F09874456FAD

Q24791524-B96F761A-1AC8-42D3-9008-C96620D797E7

Q24791524-BAF749E8-7EDE-416C-B36D-4DC3E54F80A0

P2888

Q24791524-118B266B-973F-49A6-99F4-FD93ED79A91D

P304

Q24791524-0914D2AB-C3A5-45FA-B59E-DA55913D5D52

P31

Q24791524-4FBB5A71-9E04-414A-A90F-0ACF14A8B026

P3181

Q24791524-3774013E-4908-45A4-A3B3-4E1D40F883EF

P356

Q24791524-180EAB66-3139-4821-B01C-AB2B3C57F0A5

P433

Q24791524-84D0A692-01E4-48A6-B8DF-D594EBDBA641

P478

Q24791524-FF03F5B9-E908-4F16-B20B-7C1553BB420D

P577

Q24791524-0E8A9C32-2F8F-41C9-BB02-A11AF7809292

P5875

Q24791524-EF50D216-B51A-4492-B608-F50DE8F69AB9

P6179

Q24791524-DAC446AE-EE8C-4144-ACA4-E79C94445267

P698

Q24791524-39DAE8D6-9A4D-4404-99AA-03ABA0C3820A

P932

Q24791524-D86665CC-52DF-44B9-AAE5-56083D542ED9

P3181

P356

P1433

Current controlled trials in cardiovascular medicine

P1476

Informative noncompliance in endpoint trials

@en

P2093

Boris Iglewicz

http://www.w3.org/2001/XMLSchema#string

Qi Jiang

http://www.w3.org/2001/XMLSchema#string

Steven M Snapinn

http://www.w3.org/2001/XMLSchema#string

P2860

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

Statistical considerations in the intent-to-treat principle

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Calculation of sample size in survival trials: the impact of informative noncompliance.

Sample size determination in clinical trials with time-dependent rates of losses and noncompliance.

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3870520

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1468-6708-5-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8474577

http://www.w3.org/2001/XMLSchema#string

P6179

1049708260

http://www.w3.org/2001/XMLSchema#string

P698

15233844

http://www.w3.org/2001/XMLSchema#string

P932

469444

http://www.w3.org/2001/XMLSchema#string